Hormonal Therapy Options for Endometriosis

Why Hormonal Therapy
Combined Oral Contraceptives (COCs)
Continuous vs. Cyclic Dosing
Progestin-Only Options
Levonorgestrel IUD (Mirena, Liletta)
GnRH Agonists (Leuprolide, Goserelin, Nafarelin)
GnRH Antagonists (Elagolix, Relugolix Combo)
Aromatase Inhibitors
Danazol
Choosing Between Options
Cost Comparisons
Bone Density Monitoring
Mental Health and Mood
What Hormonal Therapy Does NOT Do
Key Research Papers
Research Papers
Connections

Why Hormonal Therapy

Endometriosis lesions are estrogen-hungry. The ectopic tissue that implants on your ovaries, peritoneum, uterosacral ligaments, bowel, or bladder responds to the monthly estrogen surge the same way the lining of your uterus does: it thickens, becomes inflamed, bleeds, and releases prostaglandins and cytokines that scream pain into the surrounding nerves. Every menstrual cycle, the lesions get another push. Over years, that cycling drives scar tissue, adhesions, and central sensitization of the nervous system.

Hormonal therapy is the single most effective non-surgical way to interrupt that loop. The strategy is simple to describe and easy to misunderstand: suppress ovarian estrogen cycling, so lesions stop getting monthly stimulation, so inflammation and pain settle. Different drugs do this in different ways — some by overriding your natural cycle with a steady hormone background (the pill, progestins, IUDs), some by shutting the ovaries down entirely (GnRH agents), and some by blocking the local enzyme that makes estrogen inside lesions themselves (aromatase inhibitors).

What hormonal therapy is not: a cure. It is disease-suppressive, which means it controls symptoms and may slow progression, but the lesions remain. Stop the medication and, for most people, pain returns within one to three cycles. Understanding this up front prevents a lot of disappointment. You are managing a chronic inflammatory disease, not treating an infection.

Combined Oral Contraceptives (COCs)

Combined oral contraceptives — the familiar "birth control pill" containing both estrogen (usually ethinyl estradiol, sometimes estradiol valerate) and a progestin — are the first-line hormonal treatment for endometriosis pain. They are cheap, widely available, reversible, and work reasonably well for mild to moderate disease. Major guidelines from ESHRE, ACOG, and the American Society for Reproductive Medicine all list COCs as starting therapy when there are no contraindications.

How they work: the steady daily hormone dose shuts down your brain's signal to the ovaries (via suppression of LH and FSH), so you stop ovulating. Without ovulation, there is no luteal-phase estrogen surge, no progesterone withdrawal, and therefore no natural menstruation. The endometrial lining (both in the uterus and the lesions) stays thin and quiet.

Typical brand choices for endo pain:

Low-dose ethinyl estradiol pills (20–30 mcg) combined with levonorgestrel (Lessina, Aviane, Alesse) — classic, cheap, well-tolerated.
Drospirenone-containing pills (Yaz, Yasmin, Beyaz) — drospirenone is a progestin with mild anti-mineralocorticoid activity, often preferred in patients with bloating, PMS-like mood symptoms, or mild fluid retention.
Estradiol-valerate / dienogest (Natazia, Qlaira in Europe) — uses body-identical estradiol and the most endo-targeted progestin on the market; a reasonable option if standard pills have failed but GnRH feels like a big step.

Plan on three to twelve months to judge whether it is working. Hormonal therapy for endo is a slow improvement, not an immediate one. If pain is clearly better at three months, stay the course; if it is unchanged at six, consider switching class.

Contraindications to estrogen-containing pills are firm and non-negotiable: smoker over age 35, history of venous thromboembolism (DVT or PE) or a known clotting disorder, migraine with aura (stroke risk), uncontrolled hypertension, active liver disease, and a personal history of estrogen-sensitive cancer (breast, certain endometrial). If any of these apply, skip to progestin-only options.

Continuous vs. Cyclic Dosing

This is the single most important tweak most patients have never been told about. Standard birth-control packs contain 21 hormone pills and 7 placebo pills, engineered in the 1960s to produce a monthly "period" the Catholic Church would recognize. For contraception, that placebo week is arbitrary. For endometriosis, it is actively harmful: every placebo week, estrogen and progestin drop, the uterine lining sheds, and lesions get a miniature monthly re-stimulation.

Continuous dosing — taking an active pill every day, skipping the placebo week entirely — is the preferred regimen for endo. You simply open a new pack when you finish the 21 active pills. No withdrawal bleed, no lesion re-stimulation, dramatically less cyclical pain. Extended-cycle formulations like Seasonique (84 active / 7 placebo) or Amethyst (365 active, no placebo) package this for you, but any monophasic pill can be used continuously by skipping placebos.

Expect breakthrough bleeding in the first three to six months of continuous use. It is not a sign the pill is failing — it is the uterine lining adjusting. Most women settle into complete amenorrhea by month six. If breakthrough bleeding persists, a short planned 4-day break every three months often resets things.

Progestin-Only Options

When estrogen is contraindicated, or when COCs have not relieved pain, progestin-only therapy is the next step. Progestins suppress ovulation, thin the uterine lining, and directly down-regulate estrogen receptors on endometriotic lesions. Four options dominate:

Norethindrone acetate (Aygestin). 5–15 mg by mouth daily, titrated upward to the dose that controls symptoms without unacceptable bleeding. Cheap (often under $20/month generic), decades of track record, effective in the majority of patients. The main downside is breakthrough bleeding, which can be frequent and unpredictable in the first six months. Many patients tolerate it; others find it intolerable.

Dienogest (Visanne, Dinagest). 2 mg daily. The most rigorously studied progestin for endometriosis worldwide. In head-to-head trials against leuprolide, dienogest produced equivalent pain relief with a far better side-effect profile and roughly bone-density neutral use over 15 months. Dienogest is not FDA-approved as a standalone drug in the United States (it is available only as a component of Natazia), so U.S. patients who want monotherapy must import it through pharmacies in Canada, the UK, or Germany — legal for personal use but variable in cost. Cost ranges roughly $60–$200 per month depending on source.

Medroxyprogesterone acetate (Provera oral, Depo-Provera IM). Oral Provera 10–30 mg daily or Depo-Provera 150 mg intramuscular every three months. Effective and cheap, but two real problems: weight gain (average 3–5 kg over the first year for many users) and significant bone density loss during prolonged Depo use. The FDA carries a black-box warning limiting Depo to two years of continuous use without weighing risks. For endo, it is a reasonable short-to-medium option, not a long-term plan.

Drospirenone-only (Slynd). 4 mg daily. A newer progestin-only pill approved in the U.S. in 2019. Allows a 4-day pill-free interval without losing contraceptive effect, and has less breakthrough bleeding than norethindrone in most users. Less endo-specific research exists, but mechanistically similar to other progestins and a reasonable choice in patients who cannot tolerate norethindrone.

Levonorgestrel IUD (Mirena, Liletta)

The levonorgestrel-releasing intrauterine device delivers roughly 20 mcg of progestin per day directly into the uterine cavity, falling to about 10 mcg/day by the end of its five- to seven-year lifespan. Because the delivery is local, systemic progestin levels stay low, which often means fewer systemic side effects (mood, weight, bloating) than oral progestins.

For endometriosis, the Mirena is particularly useful when the pain picture is dysmenorrhea-dominant (severe cramping, heavy bleeding) or when adenomyosis (endometrial tissue embedded in the uterine muscle) coexists with endometriosis — a combination that is common and frequently missed. Mirena is widely considered the best non-surgical treatment for adenomyosis.

By one year, roughly 20% of users are completely amenorrheic, and most of the rest have very light spotting. Pain relief is substantial in two-thirds of endo patients over 12 months. Cost is typically covered by insurance at no out-of-pocket under ACA contraceptive rules in the U.S.; without insurance, the device itself runs about $800 plus a $200–$400 insertion fee — roughly $200/year amortized over five years, which is cheaper than almost any oral option.

Two caveats. Insertion can be painful, especially in patients who have never been pregnant or who already have pelvic hypersensitivity from endo. Ask about a paracervical block, take ibuprofen 600–800 mg an hour beforehand, and consider oral or IV sedation if you are anxious — it is a reasonable request. Expulsion risk is about 4% overall and a bit higher in the first three months and in patients with fibroids or severe dysmenorrhea. If cramping changes character or bleeding suddenly increases, have the strings checked.

GnRH Agonists (Leuprolide, Goserelin, Nafarelin)

Gonadotropin-releasing hormone agonists — leuprolide (Lupron Depot), goserelin (Zoladex), nafarelin (Synarel nasal spray) — induce a chemical pseudomenopause. Paradoxically, they work by overstimulating the pituitary so aggressively that it desensitizes and stops releasing LH and FSH entirely. With no pituitary signal, the ovaries shut down. Estrogen drops to postmenopausal levels within two weeks, and endometriotic lesions starve.

Typical course is 3 to 6 months, given as monthly (Lupron 3.75 mg IM) or three-monthly (Lupron 11.25 mg IM) depot injections. The first one to two weeks produce a flare — the initial pituitary overstimulation transiently raises estrogen, and pain can worsen sharply before improving. Bridge this with continued COC or progestin for the first 10 days.

Side effects are the side effects of menopause arriving abruptly at age 30: hot flashes, night sweats, vaginal dryness, sleep disruption, mood changes, and bone density loss averaging 4–6% over six months. Because of the bone loss, straight GnRH agonist courses are typically limited to six months lifetime without add-back therapy.

Add-back — a small dose of norethindrone acetate 5 mg daily, or low-dose estradiol 0.5 mg plus norethindrone 0.1 mg — restores enough estrogen to protect bone and soften hot flashes without giving lesions enough to re-grow. With add-back, GnRH agonist courses can safely extend to 12 months or sometimes longer, and most patients tolerate them dramatically better. Always ask for add-back. It is well-supported by guidelines and there is almost no reason to use Lupron alone.

GnRH Antagonists (Elagolix, Relugolix Combo)

GnRH antagonists are the newer, smarter version of GnRH agonists. Instead of overstimulating and desensitizing the pituitary, they directly block the GnRH receptor. This gives three big advantages: they are oral (no injections), they work immediately (no flare), and the degree of suppression is dose-dependent — you can choose partial or full ovarian shutdown.

Elagolix (Orilissa). FDA-approved for endometriosis pain in 2018. Two doses: 150 mg once daily for up to 24 months produces partial estrogen suppression (estradiol around 40 pg/mL, like early follicular phase) — less bone loss, pain relief good for most patients. 200 mg twice daily for up to 6 months produces nearly full suppression — stronger pain relief, but hot flashes and bone loss closer to full menopause. Choose based on pain severity. Side effects: hot flashes (24–46% depending on dose), headache, nausea, mood changes, measurable bone density decline especially at the higher dose.

Relugolix combination (Myfembree). FDA-approved for endometriosis pain in 2022. One pill daily that contains relugolix 40 mg plus built-in add-back (estradiol 1 mg + norethindrone acetate 0.5 mg). The add-back is integrated precisely to the "estrogen threshold" — the sweet spot where lesions stay starved but bones and vasomotor symptoms are protected. Most patients tolerate Myfembree much better than straight GnRH antagonist or agonist therapy, and the drug is approved for up to 24 months of continuous use. Bleeding, headache, and mood changes are the commonest side effects; bone loss is modest.

For most patients failing first- and second-line therapy, Myfembree is now a better choice than Lupron — it is oral, convenient, well-tolerated, and longer-duration. The major barrier is cost (see below) and insurance prior authorization.

Aromatase Inhibitors

Aromatase is the enzyme that converts androgens into estrogens. Endometriotic lesions express aromatase locally, meaning they can manufacture small amounts of estrogen themselves, independent of the ovaries. This is why some patients continue to have pain on GnRH therapy or even after menopause.

Letrozole 2.5 mg daily (occasionally anastrozole 1 mg daily) is used off-label in endometriosis, almost always combined with a progestin or continuous COC to prevent compensatory ovulation. It is particularly useful in refractory endo that has failed GnRH therapy, in deep infiltrating endometriosis, and in postmenopausal endometriosis where residual lesions continue to cause pain years after ovarian function has ended.

Side effects: hot flashes, joint stiffness and pain (the "letrozole aches," which can be substantial), bone density loss, and mood effects. Reserve for cases where simpler options have truly failed; most patients will never need it.

Danazol

Danazol is a synthetic androgen that was widely used in the 1980s. It is genuinely effective for endo pain, but the side effects — weight gain, voice deepening (sometimes permanent), acne, hirsutism, lipid derangement, mood changes — pushed it out of mainstream practice once better options arrived. Modern use is limited to occasional specialist cases and to vaginal-ring or IUD formulations under investigation. If a clinician proposes oral danazol today, ask why another option is not appropriate first.

Choosing Between Options

A reasonable stepped approach, assuming no contraindications and room to trial each option for 3–6 months:

Mild pain, no estrogen contraindication, wants contraception: continuous combined oral contraceptive. Cheap, reversible, widely available.
Moderate pain, or COC has failed, or estrogen contraindicated: progestin-only — dienogest (best evidence, import if U.S.) or norethindrone acetate (cheap, effective); alternatively the Mirena IUD.
Dysmenorrhea-dominant, heavy bleeding, or adenomyosis co-dominant: Mirena IUD first.
Severe refractory pain, failed above: GnRH antagonist — Myfembree (relugolix combo) preferred over straight agonist because of tolerability, oral route, and built-in add-back.
Failed Myfembree or not available: Lupron or goserelin with add-back for 6–12 months.
Failed all of the above, deep infiltrating disease, or postmenopausal recurrence: letrozole plus progestin, typically managed by a specialist center.

Most patients never need to escalate past step three. The mistake in either direction — staying on a pill that clearly is not working for two years, or jumping straight to Lupron before trying progestins — is what produces frustration. Reassess every three to six months, and change class if pain is not demonstrably better.

Cost Comparisons

Out-of-pocket U.S. pricing, approximate, for patients paying cash (insurance coverage varies):

Generic combined oral contraceptive: $10–$20 per month; often free with ACA-compliant insurance.
Norethindrone acetate (generic Aygestin): $15–$40 per month.
Dienogest (imported): $60–$200 per month depending on source.
Depo-Provera: $50–$150 per injection every three months.
Drospirenone-only (Slynd): $200–$300 per month without insurance; often covered with contraceptive benefit.
Mirena IUD: $0 with insurance under ACA; $800–$1,200 cash for device plus $200–$400 insertion — amortized over five years this is the cheapest option.
Lupron Depot: $1,000–$1,500 per monthly injection; $2,500–$3,500 per three-month depot. Often covered with prior authorization.
Orilissa (elagolix): $700–$1,000 per month retail; patient assistance programs available.
Myfembree (relugolix combo): $900–$1,100 per month retail; patient assistance programs available.
Letrozole (generic): $10–$30 per month — the one cheap specialist drug on this list.

Manufacturer patient-assistance programs exist for Orilissa, Myfembree, and Lupron, and can reduce out-of-pocket cost substantially for uninsured or underinsured patients. Ask your prescriber's office to help apply — they do this routinely.

Bone Density Monitoring

Bone loss is the main long-term safety issue with any therapy that lowers estrogen: GnRH agonists and antagonists, Depo-Provera, and high-dose aromatase inhibitors. Bone density drops fastest in the first six months of low-estrogen therapy, then stabilizes. Most loss is recoverable within 12–24 months after stopping, but not all of it.

Reasonable monitoring for patients on GnRH therapy or more than two years of Depo:

Baseline DEXA scan of lumbar spine and hip before starting.
Repeat DEXA annually on therapy, sooner if symptomatic.
Calcium 1,200 mg daily (from food preferentially; supplements if dietary intake is low).
Vitamin D 1,000–2,000 IU daily, with a baseline 25-hydroxyvitamin D level and target of at least 30 ng/mL. See the Vitamin D page.
Weight-bearing exercise 30 minutes most days — walking, jogging, resistance training.
Avoid smoking and limit alcohol to fewer than two drinks per day.

Mental Health and Mood

Hormonal fluctuations — up or down, starting or stopping — can destabilize mood in patients with underlying depression, anxiety, or PMDD. Dienogest, progestin-only pills, and GnRH agents are the ones most commonly associated with mood effects in clinical practice, though anyone on any hormonal therapy can experience it.

Practical rules: warn your partner and close people before starting, so they can notice shifts you miss. Track your mood weekly for the first three months — a simple 1–10 daily score in a notes app is enough. Do not start hormonal therapy during an active depressive episode if you can avoid it; stabilize mood first. Tell your prescriber promptly about any new suicidal thoughts, severe anxiety, or crushing low mood — these are legitimate reasons to change class, not reasons to power through. Switching from a progestin-dominant regimen to an estrogen-containing regimen (or vice versa) often resolves mood-related side effects that the specific hormone was driving.

What Hormonal Therapy Does NOT Do

Three truths worth internalizing up front:

It does not cure endometriosis. The lesions are still there. Stop the medication and, for most people, pain returns within one to three cycles. This is why many patients end up on hormonal therapy for decades, or cycle between hormonal therapy and surgery over a lifetime.

It does not reliably improve fertility. Suppressing ovulation while trying to get pregnant is obviously counterproductive. Some protocols use short hormonal courses before IVF — particularly "ultra-long" GnRH agonist protocols for three months preceding embryo transfer, which have evidence of improving IVF outcomes in women with endo — but for spontaneous conception, hormonal therapy must be stopped. See Fertility and Endometriosis for the full discussion.

It does not address pelvic-floor dysfunction or central sensitization. Once endo pain has been present for years, the pelvic floor muscles and the central nervous system often develop their own independent pain patterns that hormonal therapy will not touch. Shutting off the lesions reveals these — and they need their own treatment. See Pelvic Floor Therapy and Central Sensitization.

None of this is a reason not to use hormonal therapy. It is a reason to use it with clear expectations and to combine it with the other levers — surgery, physiotherapy, diet, mental health care — rather than hoping one drug will do the whole job.

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on hormonal therapy for endometriosis:

Connections

Back to Table of Contents